SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Stephen O who wrote (955)7/18/2000 7:48:51 PM
From: Edward W. Richmond  Respond to of 1321
 
Stephen, if the company meets its profitability target by Q4, I would expect to see a significant appreciation in share price. I don't see either healthcare operations or government agencies blocking access to treatment. In my opinion, public pressure will demand and get this important treatment. In two years, and the possible advent of a competing therapy, I would expect the stock price eclipse anything we have seen in the past.
Just my take on Visudyne.
Regards,
Ed



To: Stephen O who wrote (955)7/18/2000 9:22:08 PM
From: Scripts  Respond to of 1321
 
<<<So even if Miravant is 2 years away 500,000 people, your number, can be treated with Visudyne by the specialists for the next 2 years but ongoing is not a certainty.>>>

Don't bet on much change. One the medical establishment gets a good thing identified -- and paid for --it takes a lot to get them to change to something else.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News